Join the Atogepant group to help and get support from people like you.
Atogepant News
Atogepant Superior for Efficacy, Functional Measures in Migraine
THURSDAY, Dec. 26, 2024 – For adults with migraine, atogepant 60 mg once daily was superior to placebo for efficacy and functional measures of treatment across three trials, according to research...
U.S. FDA Approves Qulipta (atogepant) for Adults With Chronic Migraine
NORTH CHICAGO, Ill., April 17, 2023 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved expanding the indication of Qulipta (atogepant) ...
FDA Approves Qulipta (atogepant) Oral CGRP Receptor Antagonist for the Preventive Treatment of Migraine
NORTH CHICAGO, Ill., Sept. 28, 2021 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Qulipta (atogepant) for the preventive treatment of...
Further information
Related condition support groups
Chronic Migraine, Migraine Prevention, Migraine Prophylaxis, Headache, Migraine